解读多发性骨髓瘤中CAR T细胞后循环瘤DNA的反应动态和治疗阻力
Hitomi Hosoya1, Mia Carleton2, Kailee Tanaka2
1Division of Blood and Marrow Transplant and Cell Therapy, Department of Medicine, Stanford University, Stanford, CA, USA.
Nature communications
|February 20, 2025
概括
循环瘤DNA (ctDNA) 为多发性骨髓瘤 (MM) 管理提供了一个强大的工具. 这种方法有助于表征瘤遗传学,监测治疗有效性,并使得复发的早期检测.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 多发性骨髓瘤 (MM) 是一种无法治愈的血液性恶性瘤,经常复发.
- 目前的治疗策略需要改进监测疾病进展和治疗反应的方法.
研究的目的:
- 开发和验证循环瘤DNA (ctDNA) 试验,用于分子表征,治疗反应监测和早期检测MM的复发.
- 评估在接受抗BCMA CAR T细胞治疗的患者中ctDNA的有用性.
- 评估可测量的残留疾病 (MRD) 评估和预测临床复发的ctDNA.
主要方法:
- 来自64名新诊断或复发/耐药MM患者的412个样本的测序.
- 对ctDNA与临床生物标志物和患者结局的相关性分析.
- 在接受BCMA-CAR T细胞治疗的患者中,同时追踪ctDNA和CAR特异性无细胞DNA (CAR-cfDNA).
主要成果:
- ctDNA水平与关键的临床生物标志物和患者结果有相关性.
- 在BCMA-CAR T细胞治疗接受者中,治疗后ctDNA水平与进展时间 (TTP) 相反相关.
- 基于ctDNA的可测量的残留疾病 (ctDNA-MRD) 评估与骨髓MRD一致,可以预测临床复发.
- 通过ctDNA分析确定了耐疗克隆的出现.
结论:
- ctDNA分析为MM瘤基因组学和疾病动态提供了宝贵的见解.
- ctDNA作为监测治疗反应和检测MRD的敏感工具.
- 基于ctDNA的MRD评估可以预测复发并识别耐药性机制,支持其在MM监测和管理中的临床实用性.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

